Study of Tirzepatide for Weight Loss in Young Adults Aged 18 to 26 With Prader-Willi Syndrome, Hypothalamic Obesity, or General Obesity

What this Trial Is About

Researchers are evaluating the effects of the weight loss medication Tirzepatide in young adults aged 18 to 26 years with Prader-Willi Syndrome, Hypothalamic Obesity, or general obesity unrelated to genetic syndromes or medical conditions. The study compares how Tirzepatide influences weight and other health factors across these groups. Participants have a body mass index BMI in the obesity range. Participants will receive Tirzepatide once weekly for 48 weeks as part of the study. The study includes three groups based on their obesity type those with genetically confirmed Prader-Willi Syndrome, those diagnosed with hypothalamic obesity by a physician, and those with general non-syndromic obesity. The study involves six in-person visits and four telehealth visits over approximately 56 to 60 weeks. Throughout the study, participants will undergo medical record reviews, vital sign checks, physical exams, and anthropometric measures such as height, weight, and waist circumference. Laboratory tests including fasting blood draws and urine tests, as well as Dual-Energy Absorptiometry DXA scans and questionnaires, will be completed. Researchers will monitor changes in weight, BMI, fat mass, appetite, and various metabolic markers. The primary outcome is weight change after 48 weeks of treatment.

Tirzepatide in PWS, HO and GNSO